A concurrent HRAS mutation identified in salivary mucoepidermoid tumor patient will most likely not respond to a PI3KCA inhibitor, however, the myoepithelioma patient could benefit from off-label therapy. This evidence concerns the gene HRAS and myoepithelial tumor.